About ASLAN | ASLAN Pharmaceuticals

Popular pages

• About ASLAN | ASLAN Pharmaceuticals

  The Investor Relations website contains information about ASLAN Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

• ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides

  TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023 Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second ...

• ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose (MAD) trial in patients with moderate-to-severe atopic dermatitis (AD) On track to initiate Phas...

• ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) progressing, multiple sites enrolling; topline data expected in the first half of 2023 Alex Kaoukhov, MD, appointed a...

• ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023 New TREK-DX clinical ...

• ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023 Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1 st Internationa...